Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
复制标题
通过多变量分析评估分化抑制因子 nm23 作为急性髓性白血病的预后因素及其在其他血液系统恶性肿瘤中的应用。
作者：
A. Yokoyama;J. Okabe‐Kado;N. Wakimoto;H. Kobayashi;A. Sakashita;N. Maseki;T. Nakamaki;K. Hino;S. Tomoyasu;N. Tsuruoka;K. Motoyoshi;N. Nagata;Y. Honma
分化抑制因子nm23对小鼠和人髓系白血病细胞的分化有抑制作用。我们最近报道了nm23基因在急性髓系白血病(AML)中的过度表达，nm23-H1的高表达与AML，尤其是急性单核细胞白血病(AML-M5)预后不良有关。为了评估nm23表达作为AML预后因素的重要性，我们将其与AML中其他假定的预后因素进行了比较。对110例AML患者的临床参数与nm23表达的相关性分析表明，nm23-H1mRNA水平升高与初始化疗耐药和总生存期降低有关。用Cox比例风险模型进行的多因素分析也显示，nm23-H1mRNA水平升高对AML患者的预后有显著影响。尤其在AML-M5中，nm23-H1状态是最重要的预后因素。此外，为了确定我们是否可以将在AML中观察到的结果应用于其他血液系统恶性肿瘤，我们用逆转录聚合酶链式反应检测了149例血液肿瘤患者中nm23-H1和nm23-H2的相对水平，其中包括110例初发AML，9例初发急性淋巴细胞白血病，14例骨髓增生异常综合征，16例慢性粒细胞白血病(CML)和5例正常人。除慢性粒细胞白血病慢性期外，所有血液肿瘤组织中nm23-H1的表达均显著高于正常血细胞。Nm23可能对这些恶性血液病和急性髓系白血病的预后有影响。
The differentiation inhibitory factor nm23 can inhibit the differentiation of murine and human myeloid leukemia cells. We recently reported that nm23 genes were overexpressed in acute myelogenous leukemia (AML), and a higher level of nm23-H1 expression was correlated with a poor prognosis in AML, especially in AML-M5 (acute monocytic leukemia). To evaluate the importance of nm23 expression as a prognostic factor in AML, we compared it with other putative prognostic factors in AML. An analysis of the correlation between nm23 expression and the clinical parameters of 110 patients with AML demonstrated that increased nm23-H1 mRNA levels were associated with resistance to initial chemotherapy and with reduced overall survival. Multivariate analysis using Cox's proportional hazard model also showed that elevated nm23-H1 mRNA levels significantly contributed to the prognosis of patients with AML. Especially in AML-M5, nm23-H1 status was the most important prognostic factor. Furthermore, to determine whether we can apply the results observed in AML to other hematologic malignancies, we investigated the relative levels of nm23-H1 and nm23-H2 transcripts in 149 patients with hematologic neoplasms, including 110 with de novo AML, 9 with de novo acute lymphoblastic leukemia, 14 with myelodysplastic syndrome, 16 with chronic myelogenous leukemia (CML), and 5 normal subjects by the reverse transcriptase-polymerase chain reaction. Expression of nm23-H1 was significantly higher in all the hematologic neoplasms, except CML in chronic phase, than in normal blood cells. nm23 may have a prognostic effect in these hematologic malignancies as well as in AML.
影响因子：
15.9
作者：
KEIM, D;HAILAT, N;HANASH, SM
通讯作者：
HANASH, SM
影响因子：
10.3
作者：
STEEG, PS;BEVILACQUA, G;SOBEL, ME
通讯作者：
SOBEL, ME